Recent Updates
Recently added Catalysts

rhIGF-I/rhIGFBP-3

Phase 2

Growth Hormone Insensitivity Syndrome (GHIS) | Small molecule | Rare Disease |Insmed Incorporated|Last Updated: Jan 6, 2022

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment -

FDA Designations

No designations recorded

Clinical trial landscape

rhIGF-I/rhIGFBP-3 · 2 trials · 3 indications

Phase 2 2
NCT00577577Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1Myotonic Dystrophy Type 1
COMPLETED69 Analytics
NCT00368173IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron SyndromeGrowth Hormone Insensitivity Syndrome (GHIS)
COMPLETED- Analytics
PHASE2COMPLETED
Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
Myotonic Dystrophy Type 1Unlock trial analytics
PHASE2COMPLETED
IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome
Growth Hormone Insensitivity Syndrome (GHIS)Unlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline to Week 24 in Distance Walked as Assessed by the Six-minute Walk Test (6MWT) Distance
Baseline and Week 24

The 6MWT measured the distance in meters that participants were able to walk over a total of six minutes. After a 10 minute resting period, the participants completed the 6MWT on a hard, flat surface at baseline and at Week 24.

Change From Baseline in Daily Step Count
Baseline and Week 24

The number of steps taken per day was measured using a step activity monitor for 7 days at baseline and again at Week 24. Change from baseline scores were measured where a negative change from baseline indicates a decrease in the number of daily steps.

Peak Activity Index: Change From Baseline in Number of Steps Walked Per Minute During the 30 Minute Period of Fastest Walking
Baseline and Week 24

The peak activity index measures the number of steps walked in the 30 minutes of fastest walking that occurred in a 24 hour period. This was measured using a step activity monitor for 7 days at baseline and again at Week 24. Change from baseline scores were measured where a positive change from baseline indicates an improvement in the number of steps walked during the 30 minute period of fastest walking.

Sustained Activity Index: Change From Baseline in the Highest Number of Steps Walked Per Minute Over 20 Minutes of Activity
Baseline and Week 24

The sustained activity index measures the highest number of steps sustained over a continuous 20 minute period. This was measured using a step activity monitor for 7 days at baseline and again at Week 24. Change from baseline scores were measured where a positive change from baseline indicates an improvement in the number of steps walked over 20 minutes of activity.

Change From Baseline in the Percentage of Time That Participants Spent Inactive
Baseline and Week 24

Change from baseline scores were measured where a negative change from baseline indicates less time spent inactive.

Change From Baseline in Time Taken for Participants to Ascend and Descend 4 Stairs
Baseline and Week 24

Participants were timed on their ability to climb up 4 stairs and timed separately to climb down 4 stairs at baseline and at week 24. The stairs were free-standing or the same flight of stairs was used at each assessment. Change from baseline scores were measured where a positive change from baseline indicates an improvement in the time taken for paticipants to ascend or descend 4 stairs.

Change From Baseline in Time Taken to Traverse 30 Feet
Baseline and Week 24

Participants were timed on their ability to travel 30 feet on the same surface at each assessment at baseline and at Week 24. Change from baseline scores were measured where a positive change from baseline indicates an improvement in the time taken to travel 30 feet.

Change From Baseline in Purdue Pegboard Test Scores
Baseline and Week 24

The Purdue Pegboard Test consists of a board with two sets of 25 holes, 4 concave cups, and a number of small metal pins. Participants were required to pick up the pins from a holder and place them in the holes as quickly as possible over 30 seconds with their dominant hand. The score was calculated as the number of pins placed into holes in 30 seconds and was measured at baseline and Week 24. Change from baseline scores were measured where a positive change from baseline indicates an improvement in the number of pins placed in the board.

Change From Baseline in Forced Vital Capacity (FVC) Volume While Sitting or Lying Down
Baseline and Week 24

FVC is the volume of air that can be forcibly exhaled from the lungs after taking the deepest breath possible, as measured by spirometry.

Change From Baseline in Forced Vital Capacity (FVC) Percent Predicted While Sitting or Lying Down
Baseline and Week 24

FVC is the volume of air that can be forcibly exhaled from the lungs after taking the deepest breath possible, as measured by spirometry.

Change From Baseline in Manual Muscle Test (MMT) Scores
Baseline and Week 24

The MMT was used to assess muscle strength in the distal muscles and the proximal muscles. Distal muscles assessments included wrist extension, wrist flexion, ankle dorsiflexion and plantarflexion. Proximal muscle assessments included shoulder abduction, elbow extension, elbow flexion, hip extension, hip abduction, hip flexion, knee extension and knee flexion. In MMT, each muscle assessment was given a score of 0 to 5, where 0 indicated 'no contraction palpable' and 5 indicated 'normal strength'. The scores from each muscle were summed and the maximum overall score of all measured muscles was 140, the maximum distal score was 40 and the maximum proximal score was 80. Higher scores indicated higher muscle strength. Change from baseline scores were measured where a positive change from baseline indicates an improvement in muscle strength.

Change From Baseline in Selective Reminding Test T-Scores (Total Word and Delayed Words)
Baseline and Week 24

The Selective Reminding Test measures verbal learning and memory and involves remembering a verbal list of 12 words. Participants were required to recall the 12 words presented. Words that were missed on recall were presented again, and the process was repeated until all 12 words were correctly recalled. The total word list recall and delayed recall were calculated as T-scores. Raw scores were converted to T-score using available normative data. Change from baseline T-scores were measured where a positive change from baseline indicates improvement in performance.

Change From Baseline in Selective Reminding Test Raw Scores (Cued Recall and Recognition)
Baseline and Week 24

The Selective Reminding Test measures verbal learning and memory and involves remembering a verbal list of 12 words. Participants were required to recall the 12 words presented. Words that were missed on recall were presented again, and the process is repeated until all 12 words were correctly recalled. The cued recall scores ranged from 0-11 and multiple choice recognition scores ranged from 0-12. Change from baseline scores were measured where a positive change from baseline indicates an improvement in verbal recall and memory.

Change From Baseline in Rey Complex Figure (RCF) Test Scores
Baseline and Week 24

The Rey Complex Figure Test (RCFT) assesses visuospatial construction ability and visual memory through four different tests: copy (copying a complex geometric figure), immediate recall of the figure (drawing figure from memory at 3 minutes), delayed recall (drawing figure at 30 minutes after initial copy), and recognition score (selecting individual parts of the figure from sketches provided). Copy performances are divided into 18 components with a maximum score of 2 each. The maximum score for each figure is 36.

Change From Baseline in Letter-Number Sequencing (LNS) Test Scores
Baseline and Week 24

The LNS test from the Welchsler Adult Intelligence Scale-III was used to assess working memory. The test required that participants recall, in order, numbers and letters presented in an unordered sequence. The number of items is 21. With each item being marked 0 if reported incorrectly or 1 if reported correctly, the maximum score is 21. Raw scores were converted into T-scores using available normative data. Change from baseline T-scores were measured where a positive change from baseline indicates improvement in performance.

Change From Baseline in Trail Making Test (TMT) Scores
Baseline and Week 24

The TMT assesses executive function, sequencing, mental flexibility, visual spanning speed and motor function. In TMT Part A, the participant had to draw lines in the correct order between 25 numbers randomly arranged on the page. In TMT Part B, the participant had to draw lines between 25 numbers and letters in alternating order (e.g., 1-A-2-B...etc). Times for Part A and Part B were used to derive T-scores which can range from a minimum of 0 and a maximum of 100. Raw scores were converted into T-scores using available normative data. Change from baseline T-scores were measured where a positive change from baseline indicates improvement in performance.

Change From Baseline in the Stroop Color Word Test Scores
Baseline and Week 24

The Stroop Color Word Test measures selective attention and cognitive flexibility. The test has three parts, the Word test (reading words), the Color test (naming the ink color in which words are displayed) and the Color-Word test (saying the ink color not reading the word). An interference score was calculated from the Color, Word and Color-Word scores and is an indication of how well a person can complete a task while disregarding interfering information. Raw scores were converted into T-scores using available normative data. Scores range from 0 to 100. Change from baseline T-scores were measured where a positive change from baseline indicates improvement in performance.

Change From Baseline to Week 24 Scores on the Beck Depression Inventory II (BDI-II) Questionnaire
Baseline and Week 24

BDI-II is a validated self-reported instrument of 21 questions which are each scored 0-3. Total scores range from 0-63, with higher score totals indicating more severe depression symptoms. {0-9: indicates minimal depression; 0-18: indicates mild depression; 19-29: indicates moderate depression; 30-63: indicates severe depression. Lower scores indicate no or minimal depression, with a maximum total score of 63.

Change From Baseline in Average Fasting Glucose Concentration in the Blood
Baseline - Pre-dose and 30, 60, 90 and 120 minutes post glucose solution; Week 24 - Pre-dose and 30, 60, 90 and 120 minutes post glucose solution

Participants were administered 75 grams (g) glucose solution prior to administration of the first dose of IPlex™ and after administration of the last dose. A 2-hour oral glucose tolerance test (OGTT) was performed under fasted conditions.

Change From Baseline in Average Fasting Insulin Concentration in the Blood
Baseline - Pre-dose and 30, 60, 90 and 120 minutes post glucose solution; Week 24 - Pre-dose and 30, 60, 90 and 120 minutes post glucose solution

Participants were administered 75 g glucose solution prior to administration of the first dose of IPLEX™ and after administration of the last dose. A 2-hour OGTT was performed under fasted conditions.

Change From Baseline in Qualitative Insulin Sensitivity Check Index (QUICKI)
Baseline and Week 24

The QUICKI is based on fasting glucose and insulin measurements and are calculated using the following equation: QUICKI = 1/\[ log(fasting glucose in mg/dL) + log (fasting insulin in uU/mL) \]

Change From Baseline in Insulin Sensitivity Index-Matsuda (ISI-Matsuda)
Baseline and Week 24

The ISI-Matsuda is based on the average glucose and insulin values obtained during the entire oral glucose tolerance test and are calculated using the following equation: ISI = 10,000 / √ \[ fasting glucose (mg/dL) x fasting insulin(uU/mL) x mean glucose x mean insulin \]

Change From Baseline in Total Blood Cholesterol Level
Baseline and Week 24

A negative change from baseline indicates a decrease in total blood cholesterol level.

Change From Baseline in Total Blood Low-density Lipoproteins (LDL) Level
Baseline and Week 24

A positive change from baseline indicates an increase in total blood LDL level.

Change From Baseline in Total Blood High-density Lipoproteins (HDL) Level
Baseline and Week 24

A negative change from baseline indicates a decrease in total blood HDL level.

Change From Baseline in Total Blood Triglycerides Level
Baseline and Week 24

A negative change from baseline indicates a decrease in total blood triglycerides level.

Change From Baseline in Gastro-esophageal Reflux Disease (GERD) Symptom Frequency Questionnaire (GSFQ) Scores
Baseline and Week 24

The GSFQ contains 6 questions that assess the frequency of certain GERD symptoms and their impact on daily life. Scores were converted and reported out of 100 with higher scores indicative of more frequent and intense GERD symptoms. Change from baseline scores were measured where a negative change from baseline indicates less frequent and intense GERD symptoms.

Change From Baseline in Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) Questionnaire Scores
Baseline and Week 24

The GSRS-IBS has 13 questions aimed at identifying the frequency and intensity of IBS symptoms during the past week. Answers are given a score from 1 (no discomfort at all) to 7 (very severe discomfort). A total score was calculated and ranged from 0 to 78. A lower score indicates less discomfort from IBS symptoms. Change from baseline scores were measured where a positive change from baseline indicates increased discomfort from IBS symptoms.

Change From Baseline in Swallowing Disturbance Questionnaire (SDQ) Scores
Baseline and Week 24

The SDQ had 15 questions relating to the oral phase and pharyngeal phase of swallowing. Answers for 14 questions were assigned a number (0-3) based on a 4-point verbal scale (never, seldom, frequently, very frequently) and the last question was a yes or no question about respiratory infections. A higher score is indicative of greater swallowing issues with 44.5 as the highest possible score. A total score of ≥ 11 suggests impairment. Change from baseline scores were measured where a positive change from baseline indicates increased swallowing impairment.

Change From Baseline in Short Form (36) (SF-36) Questionnaire Scores
Baseline and Week 24

The SF-36 is a 36-item questionnaire that evaluates quality of life through physical and mental health across eight scales, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability. Change from baseline scores were measured where a positive change from baseline indicates an improvement in quality of life.

Change From Baseline in Brief Pain Inventory (BPI) Questionnaire - Severity Scores
Baseline and Week 24

The BPI contains 15 questions that assess the severity of pain and its impact or interference on functions of daily life. Pain severity was measured as the mean of 7 items of the questionnaire on an 11-point scale where 0 indicates no pain and 10 indicates the worst pain. A higher score indicates greater pain. Categories assessed include worst pain in 24 hours and average pain. Change from baseline scores were measured where a positive change from baseline indicates a worsening in pain.

Change From Baseline in Brief Pain Inventory (BPI) Questionnaire - Interference Scores
Baseline and Week 24

The BPI contains 15 questions that assess the severity of pain and its impact or interference on functions of daily life. Pain interference is measured as the mean of 7 items on an 11-point scale where 0 indicates no interference and 10 indicates complete interference. A higher score indicates greater impairment due to pain. Change from baseline scores were measured where a positive change from baseline indicates a worsening of interference due to pain.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeSUPPORTIVE_CARE

Treatment Arms

ArmTypeDescription
rhIGF-I/rhIGFBP-3EXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
rhIGF-I/rhIGFBP-3DRUG1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
placeboDRUG1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
Unlock Study Design Details

Eligibility Criteria

Age Range21 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites12

Inclusion Criteria (list is not inclusive): * A diagnosis of DM1, confirmed by DM1 genetic mutation * Ability to walk 30 feet - assistance with cane and/or leg bracing permitted * Able to self-administer study medication by subcutaneous injection or caregiver is available to administer study medica...

Countries:United StatesArgentinaAustraliaBrazilChinaEgyptGermanyIsraelItalyNorwayPeruSlovakiaTurkey (Türkiye)United Kingdom
Unlock Eligibility Criteria

Frequently asked questions about rhIGF-I/rhIGFBP-3

What is rhIGF-I/rhIGFBP-3 used for?

rhIGF-I/rhIGFBP-3 is an investigational therapy being studied for Myotonic Dystrophy Type 1 and Growth Hormone Insensitivity Syndrome (GHIS), including Laron Syndrome. It is a recombinant human insulin-like growth factor-I combined with recombinant human insulin-like growth factor binding protein-3, developed by Insmed Incorporated for rare disease indications.

What does rhIGF-I/rhIGFBP-3 target?

rhIGF-I/rhIGFBP-3 targets the insulin-like growth factor pathway. It delivers recombinant human insulin-like growth factor-I (rhIGF-I) bound to recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3), which modulates IGF-I activity in the body.

Who makes rhIGF-I/rhIGFBP-3?

rhIGF-I/rhIGFBP-3 is developed by Insmed Incorporated, a biopharmaceutical company traded on NASDAQ under the ticker INSM. The company is investigating this therapy for rare diseases including Myotonic Dystrophy Type 1 and Growth Hormone Insensitivity Syndrome.

What phase is rhIGF-I/rhIGFBP-3 in?

rhIGF-I/rhIGFBP-3 is in Phase 2 clinical development. It is investigational and not yet approved by regulatory authorities. Two Phase 2 trials have been completed, one in Myotonic Dystrophy Type 1 and one in Growth Hormone Insensitivity Syndrome, but the drug remains in clinical testing.

What clinical trials is rhIGF-I/rhIGFBP-3 in?

rhIGF-I/rhIGFBP-3 has completed two Phase 2 trials. NCT00368173 studied the therapy in children and adolescents with Growth Hormone Insensitivity Syndrome such as Laron Syndrome across multiple countries. NCT00577577 evaluated safety and efficacy in 69 adults with Myotonic Dystrophy Type 1 in the United States.

Is rhIGF-I/rhIGFBP-3 the same as IGF-I/IGFBP-3?

rhIGF-I/rhIGFBP-3 is the recombinant form of the naturally occurring IGF-I/IGFBP-3 complex. The prefix 'rh' indicates recombinant human production. In clinical trials, the drug is referred to as rhIGF-I/rhIGFBP-3, and it is being studied for Myotonic Dystrophy Type 1 and Growth Hormone Insensitivity Syndrome.